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Abstract  23 
 24 
Purpose:  Bladder cancer (BC) is a common disease with disparate treatment options and variable outcomes. 25 
Despite the disease’s high prevalence, little is known of the lived experience of affected patients. National patient 26 
experience surveys suggest that those with BC have poorer experiences than those with other common cancers. 27 
The aim of this review is to identify first-hand accounts of the lived experiences of diagnosis through to 28 
survivorship.  29 
 30 
Method: A systematic review of the qualitative evidence reporting first-hand accounts of the experiences of being 31 
diagnosed with, treated for and surviving bladder cancer.  A thematic analysis and ‘best fit’ framework synthesis 32 
was undertaken to classify the experiences.  33 
 34 
Results:   The inconsistent nature of symptoms contributes to delays in diagnosis. Post diagnosis, many patients 35 
are not actively engaged in the treatment decision making process, and rely on their doctor’s expertise. This can 36 
result in patients not adequately exploring the consequences of these decisions. Learning how to cope with a ‘post-37 
surgery body’, changing sexuality and incontinence is distressing. Much less is known about the quality of life of 38 
patients receiving conservative treatments such as Bacillus Calmette-Guerin (BCG). 39 
 40 
Conclusions: The review contributes to a greater understanding of the lived experience of bladder cancer. 41 
Findings reflect a paucity of relevant literature, and a need to develop more sensitive Patient Reported Outcome 42 
Measures (PROMs) and incorporate patient reported outcomes in BC care pathways.  43 
 44 
Implications for Cancer Survivors: Collective knowledge of the patients’ self-reported experience of the cancer 45 
care pathway will facilitate understanding of the outcomes following treatment. 46 
  47 
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Introduction 48 
Bladder cancer (BC) is the seventh most common cancer in the world [1] and is one of the most expensive to 49 
manage [2]. The disease is more common in males than females, reflecting the main etiological risk factors, i.e. 50 
cigarette smoking and occupational carcinogen exposure [3]. Despite advances in the epidemiology and treatment, 51 
relatively little is known about the experience of patients’ diagnosed with BC [4, 5]. Patient surveys have shown 52 
the experience of those with BC is one of the poorest when compared to other cancers. Potential explanations for 53 
this include absence of care planning, emotional support and poor post discharge care [6]. These factors may be 54 
compounded by the male predominance of BC and the tendency of men to internalise their illness behaviour [7].  55 
 56 
Whilst most cancers affect the well-being and quality of life (QoL) of diagnosed individuals and their caregivers, 57 
the QoL for BC patients is not well known due to a lack of disease and treatment specific validated measure(s), 58 
and a lack of large scale analyses [8-13]. Where data are available, reports are often restricted to small samples, 59 
post-treatment [14, 15] and so limit understanding of the BC patients experience following diagnosis and pre-60 
treatment experience of care (reviewed in [4]). Developing new measures which identify care needs across the 61 
patient pathway will help improve clinical practice and assist patients in the early stages of their diagnosis and 62 
treatment decision making [16]. Given that recent reviews have focussed upon quantitative data (e.g. [4]), we 63 
undertook a systematic review of the current status of qualitative data in patients with BC. 64 
 65 
In 2010, the National Cancer Survivor Initiative (NCSI) published a ‘Vision’ document [5] that reported a number 66 
of key shifts required in the approach to care for people living with and beyond cancer. One key vision was moving 67 
the focus from measuring clinical activity to measuring experience, concerns and outcomes for cancer survivors 68 
through routine use of patient reported outcome measures (PROMs). The value of qualitative research in the 69 
development of PRO measures has been recognised for some time. For example,  Duncan et al. [17] recently 70 
conducted a synthesis of the qualitative evidence to examine the quality of life domains from the patient 71 
perspective to facilitate PROM development in five specific health conditions. This article also presents a 72 
systematic search of the qualitative literature and a ‘best fit’ framework synthesis [18] to classify and enhance  73 
understanding  of the experiences of BC from the patients’ perspective.  Findings may also assist future PROM 74 
development.    75 
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 76 
Method 77 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed, 78 
including reference to the 27 item checklist (where applicable)  and four phase item flow diagram [19] – see figure 79 
1.  80 
 81 
Literature Search 82 
Medline, Psycinfo, Embase, Cinahl, Cochrane Library, Global Health, Scopus, Pro Quest (Health & Medicine) 83 
and Google Scholar were searched for articles published between January 2000 and January 2016. A combination 84 
of key words to describe the patient, patient experience, BC, treatment, and research method were used. For 85 
example to describe the patient (patient, cancer patient, surgical patient, hospitalised patient); their experience 86 
(acceptance, attitude, beliefs, opinion, satisfaction, quality of life, quality of care, understanding, feelings); the 87 
cancer (BC, urinary bladder neoplasms, bladder, carcinoma); the treatment (intravesical immunotherapy, BCG 88 
vaccine, cystectomy, surgery) and research method (interview, case studies, observations, focus group, thematic 89 
analysis), see online resource 1 for example search strategy. In addition, reference lists and citations of included 90 
studies were scanned, specific urology journals were hand searched (Current Opinion in Urology, European 91 
Urology, Urology Practice, Journal of Urology, Urology, Scandinavian Journal of Urology and Nephrology and 92 
Scandinavian Journal of Urology and Asian Journal of Urology). Lead authors (identified from the searches / 93 
included studies) and conference abstracts (APOS, BPOS) were searched. English language restriction was 94 
applied to the search. 95 
 96 
Study Selection  97 
All primary studies detailing self-reported accounts of the experience of being diagnosed and treated for BC 98 
(primary cancer) were included in the review, meaning that results are based upon the narratives of individuals 99 
with BC. Studies that reported survey data only or hypothetical data were excluded. Two authors (AE and JB) 100 
reviewed the titles and abstracts to apply the inclusion criteria and potentially eligible full text articles were 101 
evaluated by AE, JB and MT for eligibility and quality. Each article was assessed for quality using the Critical 102 
Appraisal Skills Programme (CASP) assessment tool for qualitative research [20]. All studies were included in 103 
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the review regardless of their quality rating, but the rating was used as an indication of the strength of the evidence 104 
and to inform standards required for future research into the qualitative experiences of people diagnosed with BC. 105 
Disagreements were resolved by discussion.   106 
 107 
Data synthesis  108 
Data regarding population, age range, participant numbers, diagnosis, treatment, data collection approach, and 109 
derived themes were extracted using a standardised form. A thematic analysis of all the identified lived 110 
experiences of BC, using a ‘best fit framework synthesis’ [18] was undertaken starting with very similar themes 111 
to those described by Beitz and Zuzelo [21], which were experience of diagnosis; acute care & treatment; post 112 
treatment, and the new normal.  These informed the framework as they encompassed the patients’ pathway from 113 
diagnosis to survivorship and adapting (or not) to life and thereby fit with the aims of this review. Initial allocation 114 
of experiences to the framework was undertaken by AE aided by discussion with JB and MT in uncertain cases.   115 
 116 
Results 117 
Manuscript selection 118 
In total, 2,198 manuscripts were identified, from which 14 eligible studies were selected (figure 1 and online 119 
resource 2). Most studies were North American (n=9) or British (n=3), with 1 from Italy and Sweden. Accounts 120 
of 270 participants, of which 188 (70%) were male and 76 (30%) were female (gender missing in one study, n=6), 121 
with an age range from 33-86 years are reported. Diagnoses included non-muscle invasive, muscle invasive and 122 
metastatic BC. Treatments included radical cystectomy with various urinary diversions, systemic chemotherapy, 123 
radical radiation, transurethral resection and intravesical Bacillus Calmette-Guerin (BCG). At least half of the 124 
studies focus on the experiences of radical surgery patients, other papers did not report treatments provided and 125 
only two papers focussed exclusively on BCG patients. Articles were scored for quality; with a mean quality score 126 
of 7 (range 5-9/9 points). Lower scores reflected an absence of ethical standard statements and risk or presence of 127 
bias during the process.  128 
 129 
 130 
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Figure 1: flow chart of included and excluded studies about here 131 
 132 
Patients’ experience of diagnosis 133 
This theme captures patients’ reported experience of being diagnosed with BC; including presenting symptoms, 134 
diagnostic process, pre-treatment consultations and the treatment decision-making process.  135 
 136 
Diagnosing BC: 137 
Typical symptoms of BC were visible haematuria and altered urination patterns (urgency, frequency and dysuria) 138 
[21, 22]. Patients described haematuria as deceptive due to its painless and inconsistent nature [21]. The lack of 139 
pain and understanding about BC led to a delay in seeking help [23, 21, 24]. When help was sought, some felt 140 
frustrated that their symptoms were trivialised and misdiagnosed. For example, women presenting with blood in 141 
their urine were often met with “are you sure it’s not just your menstrual cycle?” [ 21], reflecting the typical delay 142 
in referral for female patients with BC [25]. 143 
 144 
A typical response to diagnosis was shock, upset [21, 23], and devastation [26], followed by a fear of treatment 145 
[26] and an intense desire for a speedy intervention [21]. Some described feeling ‘scared to death’ and thought of 146 
their diagnosis as a death sentence [21, 26, 23] “you’re sitting there thinking I’m going to die”[23]. Hilton and 147 
Henderson [24] described this experience as ‘unknowing’ – everything a patient knows about their health is 148 
suddenly called into question and they may now  worry their overall health will deteriorate [26].   149 
 150 
Treatment Decision making: 151 
Making treatment decisions was perceived as very challenging. Patients described difficulty understanding 152 
medical explanations, treatment options and potential side effects [27] and felt uncomfortable making such 153 
decisions [21]. Cancer information became important and patients reported receiving insufficient information 154 
about self-care after treatment (surgery), finances and insurance; and subsequently many sought  information via 155 
the internet and /or support groups [27]. Worries about survival, pain, reduced sexual function and change in body 156 
image (after surgery) were often not addressed. In one recent study, only 6 out of 30 patients reported discussing 157 
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likely changes in sexual function following surgery during the treatment consultation [27]. Some patients also 158 
reported receiving conflicting treatment recommendations and felt there was a bias toward particular treatments 159 
depending on the health care professional they spoke to [21].   160 
 161 
Berry and colleagues [28] explored how patients perceived and engaged in treatment decision making. They found 162 
patients expended significant effort in identifying the best healthcare provider “one of the things I’ve always kept 163 
as a reference point is where are the centers of excellence for various treatments?” [ 28], even if this meant 164 
travelling a significant distance for treatment. In contrast, when considering treatment choice, almost half of 165 
patients’ were passive in the decision making process and accepted the clinicians’ treatment recommendation 166 
without question, but this  was not constructed as problematic by patients “it’s like, no you [clinician] tell me 167 
what to do” [28] and was most common in patients with early stage disease. Other patients sought information 168 
from the internet, family, friends, and others with knowledge / personal experience to inform discussions with 169 
their clinician. A small number reported having complete control over the decision “at the end I [patient] was the 170 
only one who would make the decision” [28]. Treatment choice was largely influenced by survival statistics but 171 
other factors , such as treatment preferences [29], age and level of recreational and work activity played an 172 
important role [28] : “I based it on the fact I’m 59 so it’s not like I’m 20 and I have to live with this bag for a 173 
hundred years”; “I’ve never had a period in my life where I wasn’t exercising so an ostomy bag was really not 174 
an option for me”  [28].  175 
 176 
Unsurprisingly, open communication was a critical and reoccurring theme throughout the patient pathway, but 177 
particularly so in diagnosis and treatment consultations [28, 23, 30].  Early impressions of interpersonal aspects 178 
of patient care are important to the patient; in particular whether they feel that they are being treated as someone 179 
who matters and is worthy of care, and being recognised and responded to as a unique individual with a particular 180 
social context [30] - “I say yes it’s like being on first name terms with some of them…oh they get to know you and 181 
you get to know them” [30]. Patients believed it was important to have ‘a conversation’ with the clinician, where 182 
the options are discussed to ensure the clinician understands the impact of treatment options on the patient’s life. 183 
The speed and momentum of diagnosis and treatment can result in patients feeling ill prepared, in particular for 184 
the side effects of treatment [28]. They wanted treatment plans to be clear, provided in a timely fashion, and 185 
consistent from professional to professional [23]. 186 
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 187 
Patients experience of acute care & treatment 188 
This theme captures patients’ experiences of preparing for treatment and their acute care. 189 
 190 
Preparing for surgery  191 
The psychological preparation for surgery can start weeks before admission [24, 31]. One patient described it as 192 
worse than the diagnosis; for her, the thought of the impending surgical procedure (vaginal reconstruction) was 193 
devastating, terrifying and she felt uncertain whether she would ever be the same again [24]. Hilton and Henderson 194 
[24] described this experience of an impending bodily change as  ‘metamorphosis’.  Physical pre-surgical 195 
procedures were also captured in detail. For example, patients recalled the onerous procedures of bowel 196 
preparation prior to surgery [21], and neobladder reconstruction patients recalled being measured and ‘tattooed’ 197 
for stoma placement prior to their surgery, even though they were not expecting a stoma. This was described as 198 
unsettling and for some the fear of the change to self following surgery felt worse than the diagnosis [21, 24].   199 
 200 
Waking up after surgery 201 
Waking after surgery is described as a feeling of ‘alienation from the body’ [32]. This encapsulates the shock and 202 
disgust some patients experience in response to their stoma, and numerous abdominal drains [21]. Simple acts of 203 
kindness are important “what a nice woman that was [nurse] when I woke up after my first operation when I 204 
opened my eyes she was sitting at my bed holding my hand now what do you think of that…that’s a good one” 205 
[30]. 206 
 207 
Post-operative care 208 
Hands-on training on patient’ stoma appliances and catheters begins in the acute recovery phase. This was a 209 
positive experience, but many felt it should have continued after discharge [27]. Although aftercare was generally 210 
good, for some, post-operative pain was not well managed, with pain management regimes leaving patients feeling 211 
“knocked out” or “mentally in the left field” [21], and disorientated to time and place [21].   212 
 213 
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Patient’s experience of non-radical surgical treatment 214 
Two studies captured non-radical surgical treatment experiences. Patients commonly reported short lived related 215 
symptoms [22, 26]. Patients receiving BCG treatment reported abdominal pain, painful, urgent and more frequent 216 
urination [22]. Some also reported passing blood clots, blood in the urine, flu like symptoms, fatigue and soreness 217 
at the catheter site [22]. Clark [22] interviewed patients who had undergone TURBT and those patients described 218 
painful and urgent urination, knife like stinging and passing blood clots – “it was just the initial shock when you 219 
put that thing in, and the first time you go to the potty and urinate that hurt. That hurt like hell”. However, 220 
symptoms were generally temporary.  221 
 222 
Patients experience post treatment  223 
This theme mostly captures the period shortly after treatment, during which patients experience immense change 224 
and details the ways in which people learn to adapt to new, often distressing experiences.  225 
Post-surgery recuperation was long and something patients felt they needed support with [21]. It was described 226 
by one patient as “the point I became a cancer survivor” [24]. Hilton and Henderson [24] referred to this 227 
experience as ‘an unfolding path’ – recuperation was a time of immense change; encompassing new experiences, 228 
new learning and adaptation both physically and psychologically [21, 23, 24]. Weight loss following surgery was 229 
common, and patients felt exhausted and weak on their return home. Although they felt unhappy about lost vitality 230 
there was a sense of acceptance that they needed to pace their activities and some employed coping strategies, 231 
such as starting walking routines to regain strength [21]. 232 
 233 
Support of family and friends was especially valuable at this time, though paradoxically this was a time when 234 
some experienced disappointment and difficulty with close relationships; a few patients reported feeling 235 
disappointed by the lack of support and felt as though they were being treated differently [23].   236 
 237 
Patients’ experience of homecare was variable and it was a lottery in terms of how much aftercare they might 238 
receive [23]. Knowledge and expertise to deliver homecare to patients following a radical cystectomy varied – 239 
“the homecare, nobody, not one person knew or had any experience with this. They had experience with bowels 240 
but not bladder” [23].  241 
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 242 
New experiences were often unexpected and distressing. For example, patients reported not being told how they 243 
could deal with incontinence. Many reported initiating their own strategies such as wearing pads at night, changing 244 
underwear style, only wearing black trousers so leakage wouldn’t show, and establishing bladder schedules; for 245 
example, setting alarms to go off through the night to ensure regular voiding[23, 21], in the absence of  education 246 
from healthcare services [23]. Some neobladder patients had to learn to self-catheterise this felt easier than 247 
learning to void their neobladder. Mechanics of voiding the neobladder very different to their original bladder and 248 
more redolent of defecation in that they needed to “force it out” and “strain” [21]. Self-catheterising for some 249 
however felt disgusting and was avoided [21].  250 
 251 
The New Normal  252 
Having experienced a period of immense change, this theme captures the next phase, referred to as the ‘new 253 
normal’ [21]. Here patients describe their quality of life post treatment i.e. their experience of adapting (or not) to 254 
new toileting characteristics; new ways of being sexual; and living with the lifelong threat of cancer.  255 
 256 
Quality of life (QoL) following treatment for BC was mixed for both surgical and non-surgical patients. Patients’ 257 
reported both negative and positive aspects, but it was also something fluid and it fluctuated over time [15, 29]. 258 
For example, Cerruto and colleagues [15] explored the quality of life of a cross section of patients (one-year post 259 
surgery up to 30 years) who had an ileal conduit following a radical cystectomy . They presented patient profiles 260 
at one, three, five, seven, and plus seven years post-surgery. One year post surgery, QoL was reported to be good 261 
/ unchanged for some, but for others it was worse, with poor sleep and being dependent on others to manage their 262 
ostomy notable areas of concern. By three years, most reported having poor QoL; main areas of difficulty were 263 
continued dependence on partners to manage their ostomy, concern about leakage and smell of urine, and 264 
subsequent decline of social activities. Worsening of QoL over time was reported for surgical and non-surgical 265 
populations and attributed to a decreasing optimism about recovery [15, 29] and for surgical patients, the 266 
overwhelming feeling of not being the same [15]. Loss of friendships and the detrimental impact on social life 267 
was also reported by Persson and Hellstrom [32] but they noted that these occured quite soon after surgery when 268 
patients were faced with who, and how to tell, and how people would react.  269 
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 270 
By five years post treatment, quality of life had improved and patients reported feeling in a better state of health 271 
compared to pre-surgery. Cerruto and colleagues [15] attributed this improvement to adaptation. Patients reported 272 
feeling less dependent on partners, problems such as urinary leakage remained but  these were managed;  “I don’t 273 
have anxiety about my condition, there are some precautions that should be observed, I must be careful that there 274 
are no leaks but it happens rarely in my case and I can live almost normally” [15].  By seven years post- surgery 275 
social relations had recovered and activities of daily living felt less restricted. This finding was also supported by 276 
Foley et al [33] who explored the cancer experience of long term survivors and found over time survivors had 277 
acquired a greater appreciation for life.   278 
However, some concerns persisted over time; for surgical patients this included lack of sexual activity and physical 279 
complications such as hernias, urinary tract infections and peristomal skin lesions etc. which affect ostomy 280 
management and risk leakage [15]. Long-term effects of cancer were described by survivors as ‘a constant’ in 281 
their lives and as a reminder of their cancer [34, 21].   282 
 283 
Accepting incontinence  284 
Incontinence following surgery was generally permanent and learning not to be embarrassed about leakage was 285 
key to successful management [21]. New routines to respond to new toileting characteristics were commonplace 286 
[21, 27]. Some patients described difficulties and subsequent adaptations related to returning to work. For 287 
example, finding a clean place to self-catheterise away from home was described as difficult, particularly for men. 288 
Male public toilets were often perceived as dirty, and sitting on the toilet seat was unfamiliar and frustrating. For 289 
some men this resulted in a reluctance to travel, or where necessary holding large volumes of urine to avoid using 290 
public toilets. For some, a change in toilet characteristics also extended to their bowels; some experienced chronic 291 
diarrhoea and unpredictable flatulence [21, 32]. Patients described locating toilets ahead of time as a protective 292 
strategy and planning their toilet use became a major priority [21, 27]: “If you go to some function probably the 293 
first thing you seek out is the toilet”; “Life is normal. It’s almost as if it didn’t happen except for the inconvenience 294 
of having to sit and plan where I go based on having to go to the bathroom” [21].  295 
 296 
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Despite understanding the importance of hydration, many surgical participants reported not drinking enough. For 297 
some this was because of the need to subsequently empty their bladder which meant staying closer to a toilet, 298 
which increased isolation as patients remained at home; for others it was about managing continence, with some 299 
patients avoiding beer as this often resulted in night time leakage [21].  300 
Ongoing fears included leakage of gas and odour, and visibility of the stoma [32]. Patients often selected different 301 
clothes to minimise visibility and damage to the stoma (e.g. wearing loose dresses, supporting the stoma with 302 
suspenders [32]). Concerns about visibility also resulted in changes to social activities, for example avoidance of 303 
swimming pools [32].   304 
 305 
Changing sexuality 306 
Changes in sexuality were reported by men and women [27] who had undergone non-surgical  [35, 26] and radical 307 
surgical treatment [35, 21, 23]. Non-radically treated patients usually reported a short period of abstinence due to 308 
fear of contamination of their partner with the treating agents [35, 26], but for some abstinence seemed more 309 
permanent “we don’t have sex because of that stuff they were putting in me. I still get an erection and masturbate 310 
and I don’t tell her about that but I do and when I come it doesn’t come out like it used to because of that irritation 311 
in there“ [35]. For radical surgical patients, despite having prior knowledge about the impact on sexual function, 312 
i.e. impotence for men, vaginal shortening / dryness for women, the reality was still a shock. Men in particular 313 
had been certain that it would not be the case for them and described impotence as a loss of their manhood which 314 
led to other ways of achieving an erection [35, 27], but this was often met with disappointment [21]; “no more 315 
sex life, I feel destroyed physically, emotionally. Once I was a master of myself, now I depend on my wife. The 316 
surgery carried away all that I had” [15]. For others, sexual relationships were re-established but in a different 317 
way; “BC has changed our sex life a bit, we still have sex but it’s different now, well obviously it’s different for 318 
me. Since I can’t have normal intercourse it’s a lot of foreplay but I enjoy that too. It’s not as good as it was 319 
before but it’s still pretty good, I bought a vibrator so she can still have orgasms – it changed the dynamic of sex, 320 
you know it’s more to make sure she has an orgasm” [35].  321 
 322 
Post-surgery, women reported physical and psychological concerns about sex [35, 23, 27], with  the loss of 323 
physical intimacy commonly reported  “ sometimes it’s almost a platonic relationship” [ 35]. The appearance of 324 
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the stoma and the bag were of concern for some as they perceived it to be off-putting sexually [35, 23, 27, 32], 325 
with some fearing leakage from the stoma during sex [23]; “not in a million years would I let anybody close to 326 
me with this stoma and bag and all that, I’m disgusting. How it looks, I mean I have a bag of pee hanging in front 327 
of me, I find it revolting I’m sure anyone else would”  [23]. 328 
 329 
The degree of acceptance about loss of sexual function was reported to be influenced by age, stage of life, and 330 
how much importance a couple placed on sex [23]. In contrast, re-establishing a sexual relationship after BC was 331 
influenced by good communication between partners [35]. Interestingly, despite how common sexual problems 332 
seem to be amongst BC survivors, very few sought professional assistance [27], with Mohamed and colleagues 333 
positing that this was perhaps due to the fact that many were grateful to be alive [27].   334 
 335 
Living with the lifelong threat of cancer  336 
A ‘deal with it’ and ‘just take it as it comes’ attitude were commonplace [21, 33, 29, 34]. Survivors reported being 337 
very aware that many people die from BC and so a stoical and optimistic attitude to new experiences soon 338 
developed [21, 23, 33]. Similarly, living each day and having a new found sense of appreciation for their life was 339 
also apparent and may be partly attributed to the perception of cancer as a lifelong threat [21, 27, 34]. Follow up 340 
schedules proved to be a constant reminder of  how fragile life can be [21, 34] and many survivors reported that 341 
support from family and friends had been vital throughout their journey with cancer [34, 29].   342 
See online resource 3 for a preliminary conceptual framework of the patients’ experience of being diagnosed with 343 
bladder cancer through to survivorship. 344 
 345 
Discussion  346 
This is the first systematic review of qualitative evidence focusing upon first-hand accounts of the lived experience 347 
of BC. The review identified the significant impact of this disease upon the patient and their next of kin, and that 348 
currently there is little attention paid to this by BC care practitioners. Most of the data reported events at the 349 
beginning (at diagnosis) and end (life after treatment) of the patients’ pathway and there was an over-350 
representation of patients undergoing radical surgery, when the majority of patients receive non-radical 351 
(conservative) treatments. As the concerns of those undergoing conservative treatments cannot be assumed to be 352 
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the same as those of the RC population the review highlights the need for more qualitative research to inform 353 
understanding of the experiences of this population.  354 
 355 
Sexual concerns were especially common with an unmet need for information and support [35, 21, 23, 27, 32, 356 
26], which support the findings of a recent PROM pilot report [36]. The fact that very few patients reported 357 
receiving help for sexual distress is a concern [27] and suggests perhaps the shift toward exploring the patients’ 358 
holistic experience, in particular their sexual experience, as set out by the National Cancer Survivorship vision 359 
has not yet been reached [5]. The findings of the review suggest that  health professionals need to be more 360 
proactive in eliciting areas of distress and, given the gender specific concerns highlighted in this review tailored 361 
interventions would be more appropriate [27]. 362 
 363 
Body image was an important concern for those undergoing surgery. Patients’ reported experiencing significant 364 
alteration to their body [32] and women in particular reported feeling unsexual [35, 23, 27, 32]. Visibility of the 365 
stoma was problematic and resulted in patients’ altering clothing and social activities [32]. Concerns about body 366 
image were also reported in the PROM pilot report and the findings of this review evidence that conclusion [36].  367 
Only one (excluded) study found  body image not to be important[37], but this may be due to those authors asking 368 
patients to consider a future event (impact of surgery) on body image; it is not clear whether patients were 369 
specifically asked about appearance post-surgery, and given the duration of the interviews (16 minutes on average) 370 
it seems unlikely that any discussion would have been in-depth. Encouraging patients to reflect on their 371 
experiences in some depth enables a more valid disclosure of concerns [32], which might account for the disparate 372 
findings. 373 
 374 
Less frequently described but nonetheless explored were patients’ experience of acute care and discharge and this 375 
review highlights how some of the most basic acts of kindness, such as holding a patients hand on waking from 376 
surgery can make such a difference to their experience.  377 
 378 
This review identifies a relatively neglected area of cancer and the poor level of evidence in this field. It offers an 379 
understanding of the patient experience pre-diagnosis through to survivorship, complementing a recent BC PROM 380 
pilot [36] and ongoing work in BC QoL development to develop ways to comprehensively assess sexual [8] and 381 
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body image issues in particular [38]. It also serves as a useful starting point for developing teaching / training 382 
materials.  Knowledge of the patient experience from diagnosis through to survivorship and highlighting the 383 
challenges in reporting concerns is valuable to new and existing health professionals tasked with shifting the focus 384 
from clinical activity to patient experience. Finally, it’s a response to patients’ hopes for professionals to better 385 
understand their experience and in particular the impact of bodily and sexual changes [23]. 386 
 387 
Limitations 388 
The review only included articles in English language and most of the included studies were carried out in North 389 
America (within a specific healthcare system). As such it may limited understanding of a more global picture of 390 
patients’ experience with BC. The review applied a date limitation from 2000 to present. Although this will have 391 
restricted our search and subsequently missed articles of relevance, it was an attempt to capture patients’ 392 
contemporary experiences of clinical services and treatments.  In synthesising the data from all the studies, 393 
irrespective of their cancer stage and treatment, subtleties in relation to quality of life, need etc. associated with 394 
certain treatments or extent of illness will have been missed. Nevertheless, several themes identified in the review 395 
are expected to be common throughout the illness trajectory and helpful in addressing future care irrespective of 396 
stage / treatment. 397 
 398 
Recommendations 399 
The findings of this review are relevant and important to the field but reflect a paucity of relevant literature. Prior 400 
to the development of any new measure a clear conceptual framework is needed [39-41] and this review suggests 401 
that there are gaps in our understanding that need to be filled before high quality, sensitive measure of quality of 402 
life can be developed for this population. This article offers the beginnings of a conceptual framework (see online 403 
resource 3); however to develop a robust framework more research is needed. Future research should aim to 404 
improve reporting of qualitative findings relating to BC, should include larger numbers of patients (and caregivers) 405 
receiving non-radical treatments, and should include longitudinal studies to capture change over time. With this 406 
in mind, authors are now undertaking longitudinal surveys into the quality of life in patients being treated for and 407 
after a diagnosis of BC, e.g. the OTIS study 408 
[http://www.abdn.ac.uk/hsru/research/assessment/interventional/otis/]. 409 
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 410 
Implications for practice 411 
The review highlights that a better understanding of the patients experience throughout each stage of their pathway 412 
could be gleaned. It is clear patients’ experience varies and some require more or less support than others at 413 
different points along the patient pathway. Support and informational needs may be gender specific and may differ 414 
in intensity for example for those who may not have support from family and / or friends.  415 
 416 
Conclusion 417 
The findings contribute, through a qualitative synthesis, to a greater understanding of the lived experience of BC. 418 
The review has pooled the evidence making it more accessible to individual centres where numbers of patients 419 
with BC may be small, thus restricting knowledge of the full effects of cancer for this group of patients.  This 420 
might also explain why the patient experience for this group of patients has received less attention, compared to 421 
other cancer types (e.g. breast). It is noteworthy that these experiences are identified from self-reports, which 422 
suggests that discussion of them might be incorporated into the clinical pathway when appropriate. The findings 423 
identify the impact of BC upon the lived experience and suggest a need to embed PROMs within care pathways 424 
and to encourage care providers to understand their importance.   425 
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